All In Biotech

Drug Trial Radar · NCT06502964

Study of ALTO-101 in Patients With Schizophrenia

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Jun 11, 2024

Primary completion

Feb 2026

Study completion Mar 2026

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.

Conditions

  • Schizophrenia
  • Cognitive Impairment

Interventions

  • ALTO-101Drug

    ALTO-101 patches

  • ALTO-101 Transdermal Delivery SystemDevice

    ALTO-101 transdermal delivery system

  • PlaceboDrug

    Inactive placebo patches

  • Placebo Transdermal Delivery SystemDevice

    Placebo transdermal delivery system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Theta band activityTime frame: Treatment Period 1 - Day 6 and Day 11; Treatment Period 2 - Day 6 and Day 11

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site 5038

    Garden Grove, California · Recruiting

  • Site 5063

    Los Angeles, California · Recruiting

  • Site 5106

    Orange, California · Recruiting

  • Site 5035

    Walnut Creek, California · Recruiting

  • Site 5060

    Hollywood, Florida · Recruiting

  • Site 5015

    Tampa, Florida · Recruiting

  • Site 5064

    Snellville, Georgia · Recruiting

  • Site 5056

    Chicago, Illinois · Recruiting

  • Site 5062

    Gaithersburg, Maryland · Recruiting

  • Site 5124

    Belmont, Massachusetts · Recruiting

  • Site 5108

    New York, New York · Recruiting

  • Site 5077

    New York, New York · Recruiting

  • Site 5109

    New York, New York · Withdrawn

  • Site 5126

    White Plains, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.